See the DrugPatentWatch profile for cosentyx

At this time, there are no generic versions of Cosentyx (secukinumab) available on the market. Cosentyx, which is manufactured by Novartis, is a biologic medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

The patent for Cosentyx is set to expire in the United States in 2024 [1]. This means that, barring any legal challenges or extensions, generic versions of Cosentyx may become available after this date. However, it's important to note that the development and approval of generic versions of biologic medications can be a complex and time-consuming process.

According to DrugPatentWatch.com, there are several companies that have filed for tentative approval for generic versions of Cosentyx [2]. These companies include Amgen, Sandoz, and Mylan. However, it's important to note that tentative approval does not guarantee final approval or the timeline for when a generic version may become available.

In summary, while there are no generic versions of Cosentyx currently available on the market, there are several companies that have filed for tentative approval for generic versions. The patent for Cosentyx is set to expire in 2024, but the development and approval of generic versions of biologic medications can be a complex and time-consuming process.

Sources:

1. Novartis. (2021). Secukinumab (Cosentyx). Drugs.com. <https://www.drugs.com/history/cosentyx.html>
2. DrugPatentWatch.com. (2022). Secukinumab (Cosentyx). <https://www.drugpatentwatch.com/drugs/secukinumab>